Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies.
Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.
Means
R T
RT
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Olsen
N J
NJ
Krantz
S B
SB
Dessypris
E N
EN
Graber
S E
SE
Stone
W J
WJ
O'Neil
V L
VL
Pincus
T
T
D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D001772:Blood Cell Count; D001853:Bone Marrow / Q000473:pathology; D003114:Colony-Forming Units Assay; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D008875:Middle Aged; D011994:Recombinant Proteins; D014805:Vitamin B 12 / Q000097:blood
D011994:Recombinant Proteins; D004921:Erythropoietin; D014805:Vitamin B 12